Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 1996

View Archived Issues

NK1 antagonists from Glaxo Wellcome

Chiron describes a new opiate receptor ligand

Delta-opioid agonists for pain

Controlled-release oral analgesic formulation claimed by Euroceltique

Divestment of antimigraine treatment from Glaxo Wellcome to Zeneca

Retinoid compounds for dermatological disorders

Liarozole claimed for inhibiting calcitriol metabolism

Allergan discloses compounds with retinoid-like activity

Seratrodast claimed for the treatment of atopic dermatitis

Antibacterial agents disclosed by Hokuriku

Natural antibacterial agent reported by Korean researchers

Antibacterial 2-pyridones, a novel class of DNA gyrase inhibitors

Merck & Co. discloses novel antifungal agent

Antirhinovirus compounds from Lilly

New HIV protease inhibitors from Searle

CMV protease structure solved

Reticulose study in AIDS patients

Antiinfective R&D at Toyama

Antiinfective drugs in development at Daiichi

COX-2 inhibitors from Merck Frosst

A new class of selective COX-2 inhibitors from Merck Frosst

Procter & Gamble discloses new matrix metalloproteinase inhibitors

Inhibitors of cytokine production reported by SmithKline Beecham

Dual TNF production and PDE IV inhibitor from Pfizer

Progress in arthritis at Toyama

New consensus interferon from Amgen

Generic ciclosporin progressing ahead of schedule

BioTransplant licenses bone marrow processing device for use in organ transplantation

Improved camptothecin derivatives

The Liposome Company prepares and formulates new taxanes

IL-2 receptor-binding polypeptide described by Boehringer Ingelheim

Antiangiogenic eponemycin analogues

Phase I trial of a new antiangiogenic agent from Daiichi

Antitumor agents from Samjin

Dolastatin 10 mimic dolaphenine androstane

Site-specific catalytic cleavage of RNA achieved with ribozyme analogue

DNA repair gene isolated

Expanded approval sought for Photofrin

Cytoprotective agent receives broad approval in Australia

Chugai's anticancer R&D pipeline

Daiichi's anticancer drugs in development

U.S. approval for glaucoma medication

New estrogen agonists and antagonists

Novel treatment for bone loss

Vitamin D3 derivatives for osteoporosis

Warner-Lambert profiles ACAT inhibitors with hypocholesterolemic and antiatherosclerotic activity

Rapamycin in anemia

Chugai's metabolic drug R&D pipeline

Known antipsychotic claimed for drug dependence

First launch for inhaled smoking cessation product

DNA diagnostic for hereditary hemochromatosis

New test for early heart attack detection

NDA filed for ultrasound contrast agent

New diagnostic for clotting risk approved

First blood test for the management of osteoporosis cleared for marketing

Whole-blood HIV antibody test approved in Russia

Daiichi's diagnostics pipeline

New compounds from Roche with affinity for benzodiazepine receptors

Merck & Co. synthesizes dopamine D4 receptor ligands

A major breakthrough in the treatment of schizophrenia

Broad patent coverage for Genelabs' drug discovery tool

Sugen and ArQule drug discovery collaboration

Hybridon enters research collaborations for antisense therapies

Proposed acquisition agreement between Genzyme and Neozyme II

Stryker acquires Osteo

ImmunoTherapeutics name change

Dopaminergic agents claimed by Sandoz

New formulation of selegiline

New treatment strategy for Parkinson's disease introduced

Rhodanines for multiple sclerosis

Side effects of botulinum toxin A in the treatment of craniocervical dystonias

Hoechst Marion Roussel claims compound for neurodegenerative disorders

Lilly reports new treatment for attention deficit/hyperactivity disorder

Inhibitors of C1r for Alzheimer's disease

New cholinergic channel activators described by Abbott

Neuronal calcium channel antagonists for stroke

Antioxidants isolated by Japanese researchers

CNS research at Toyama

Chugai's CNS pipeline

Progress in CNS drug development at Daiichi

Improved agents for asthma

Novel PAF and 5-LO inhibitors reported by Sunkyong

Potential antiasthmatic agent from Lipha

C5a receptor required for host defense in the lung

Selective dual inhibitor of PDE I and PDE V from Schering-Plough

Merck & Co. describes endothelin antagonists

Warner-Lambert focuses on endothelin antagonists

IVAX receives approval for generic antihypertensive drug

Researchers isolate sodium pump inhibitor from human placenta

Inhibitors of ceramide-mediated signal transduction

Nebivolol claimed for oxidative stress-related disorders

Antiarrhythmic peptides claimed by BASF

Pharmacia & Upjohn discloses class III antiarrhythmic agents

Mitsui Toatsu claims long-acting oral form of MS-551

Vasopressin antagonists from American Cyanamid

New TNF-alpha inhibitors reported by Celgene

Roberts cleared to market cardiovascular orphan drug

Daiichi's broad cardiovascular pipeline

First human trial for transgenic product

Promising phase I data reported for oral heparin

Antiplatelet agents reported by Lilly

Review on gpIIb/IIIa antagonists for ischemic complications

R&D in blood coauglation at Daiichi

Development of VML-252 progresses

Evaluation of potential therapies in maintaining remission in Crohn's disease

VML-295 clinical update

New agents for disorders of gastrointestinal motility

Anticholestatic drug accepted for review in the treatment of primary biliary cirrhosis

Another Asian approval obtained for SciClone's Zadaxin

Toyama's gastrointestinal R&D

Gastrointestinal R&D at Daiichi

Achiral inhibitors of carnitine palmitoyltransferase I

New treatment for diabetic keratopathy

Orally active GH secretagogues with a short duration of action

Danish approval for testosterone patch

A safe, effective and economical contraceptive method

Endocrine R&D at Chugai

Endocrine research at Toyama

Stroke Update